FDA Advisers Recommend Approving HPV DNA Test as Primary Cervical Screening Tool — Physician’s First Watch
FDA Advisers Recommend Approving HPV DNA Test as Primary Cervical Screening Tool
By Amy Orciari Herman
An FDA advisory panel voted unanimously on Wednesday to recommend approval of human papillomavirus DNA testing as an initial, standalone cervical screening test for women aged 25 and older, the New York Times reports.
The Times points out that if the FDA chooses to follow the panel's recommendation, then initial, solo HPV testing will become another screening option. Currently, U.S. guidelines recommend that women aged 21 through 29 undergo Pap testing every 3 years and those aged 30 to 65 undergo Pap testing alone every 3 years or cotesting with HPV DNA testing and Pap smear every 5 years.